For long-term secondary prevention of MI, the use of P2Y12 monotherapy has a borderline advantage over aspirin alone and does not affect bleeding, according to a meta-analysis of nine randomized ...

Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

Please provide your email address to receive an email when new articles are posted on . In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation ...

In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Background: The initial results for CURRENT-OASIS 7 were presented at the European Society of Cardiology Congress 2009 in Barcelona. To date, final analyses of the study have not been published in a ...

A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...

Idorsia Ltd (IDIA.SW) today announced that Phase 2 clinical studies with selatogrel (recommended INN for ACT-246475), Idorsia`s P2Y12 receptor antagonist, in patients with stable coronary artery ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

What The Study Did: In this randomized clinical trial with 562 noncritically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor combined with a therapeutic dose of heparin didn’t ...